{"id":541040,"date":"2021-09-22T09:03:46","date_gmt":"2021-09-22T13:03:46","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-to-present-at-the-cantor-virtual-global-healthcare-conference\/"},"modified":"2021-09-22T09:03:46","modified_gmt":"2021-09-22T13:03:46","slug":"akari-therapeutics-to-present-at-the-cantor-virtual-global-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-to-present-at-the-cantor-virtual-global-healthcare-conference\/","title":{"rendered":"Akari Therapeutics to Present at the Cantor Virtual Global Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">NEW YORK and LONDON, Sept.  22, 2021  (GLOBE NEWSWIRE) &#8212; Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and\/or leukotriene (LTB4) systems are implicated, today announced that Clive Richardson, Chief Executive Officer, will present at the Cantor Virtual Global Healthcare Conference on Thursday, September 30, 2021 at 1:20 p.m. ET.<\/p>\n<p>Investors interested in arranging a virtual meeting with the Company&#8217;s management during the conference should contact the Cantor conference coordinator. A webcast of the Company\u2019s presentation will be available by visiting \u2018Events\u2019 in the Investor Relations section on the Company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ElmdqfaMP6-ochIjq46boXCdeAni-cgKhLfqSCL4Q2x2CxG-I_hnJ0xKqwnMpfyrPVGjY75aiHPejaTKHKJTrQ==\" rel=\"nofollow noopener\" target=\"_blank\">www.akaritx.com<\/a>. A webcast replay will be accessible for 90 days following the event.<\/p>\n<p>\n        <strong>About Akari Therapeutics<\/strong>\n      <\/p>\n<p>Akari is a biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically for the treatment of rare and orphan diseases, in particular those where the complement (C5) or leukotriene (LTB4) systems, or both complement and leukotrienes together, play a primary role in disease progression. Akari&#8217;s lead drug candidate, nomacopan (formerly known as Coversin), is a C5 complement inhibitor that also independently and specifically inhibits leukotriene B4 (LTB4) activity. Nomacopan is currently being clinically evaluated in four areas: bullous pemphigoid (BP), thrombotic microangiopathy (TMA), as well as programs in the eye and lung.<\/p>\n<p>\n        <strong>Cautionary Note Regarding Forward-Looking Statements<\/strong>\n      <\/p>\n<p>Certain statements in this press release constitute \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. You should not place undue reliance upon the Company&#8217;s forward-looking statements. Except as required by law, the Company undertakes No obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this press release.\u00a0\u00a0 These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control. Such risks and uncertainties for our company include, but are not limited to: needs for additional capital to fund our operations, our ability to continue as a going concern; uncertainties of cash flows and inability to meet working capital needs; an inability or delay in obtaining required regulatory approvals for nomacopan and any other product candidates, which may result in unexpected cost expenditures; our ability to obtain orphan drug designation in additional indications; risks inherent in drug development in general; uncertainties in obtaining successful clinical results for nomacopan and any other product candidates and unexpected costs that may result therefrom; difficulties enrolling patients in our clinical trials; our ability to enter into collaborative, licensing, and other commercial relationships and on terms commercially reasonable to us; failure to realize any value of nomacopan and any other product candidates developed and being developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; inability to develop new product candidates and support existing product candidates; the approval by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) and any other similar foreign regulatory authorities of other competing or superior products brought to market; risks resulting from unforeseen side effects; risk that the market for nomacopan may not be as large as expected; risks associated with the impact of the COVID-19 pandemic; inability to obtain, maintain and enforce patents and other intellectual property rights or the unexpected costs associated with such enforcement or litigation; inability to obtain and maintain commercial manufacturing arrangements with third party manufacturers or establish commercial scale manufacturing capabilities; the inability to timely source adequate supply of our active pharmaceutical ingredients from third party manufacturers on whom the company depends; unexpected cost increases and pricing pressures and risks and other risk factors detailed in our public filings with the U.S. Securities and Exchange Commission (SEC), including our most recently filed Annual Report on Form 20-F filed with the SEC. Except as otherwise noted, these forward-looking statements speak only as of the date of this press release and we undertake no obligation to update or revise any of these statements to reflect events or circumstances occurring after this press release. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release.<\/p>\n<p>\n        <strong>For more information<\/strong>\n      <\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Peter Vozzo<br \/>Westwicke\/ICR<br \/>(443) 213-0505<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=A7x_d3VlwWYwcxCUZ8Z4d2kK7un7sEq7RWolw_Cf18fDVpjSvPPU1V5pjH4st6gF-Sj1Oq7kkGJBwgQzdBvQAMiH_pSWX_Ozq-xq3YZDZrQ=\" rel=\"nofollow noopener\" target=\"_blank\">peter.vozzo@westwicke.com<\/a>\u00a0<\/p>\n<p>\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Sukaina Virji \/ Ashley Tapp \/ Maya Bennison<br \/>Consilium Strategic Communications<br \/>+44 (0)20 3709 5700<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rL-9p9xoJ0wW61uK-b6GDqR2rzFa2PwismddeJsp6OF2FCsVUlvpGgnaGzU8rQxMkqkPfTiNv4xKV4NQ9AGsxlpITzTlj7soaC2j3IWMM2c=\" rel=\"nofollow noopener\" target=\"_blank\">Akari@consilium-comms.com<\/a>\u00a0<\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMzMDQxNiM0NDE4MjQ3IzIwMjAyNjM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/YzIyZTMzOTctZGJhNi00ODM0LTg1ZTctZDhhYTY2ZmI4NTExLTEwMzE4MzU=\/tiny\/Akari-Therapeutics-Plc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK and LONDON, Sept. 22, 2021 (GLOBE NEWSWIRE) &#8212; Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and\/or leukotriene (LTB4) systems are implicated, today announced that Clive Richardson, Chief Executive Officer, will present at the Cantor Virtual Global Healthcare Conference on Thursday, September 30, 2021 at 1:20 p.m. ET. Investors interested in arranging a virtual meeting with the Company&#8217;s management during the conference should contact the Cantor conference coordinator. A webcast of the Company\u2019s presentation will be available by visiting \u2018Events\u2019 in the Investor Relations section on the Company\u2019s website at www.akaritx.com. A webcast replay will be accessible for 90 days following the event. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-to-present-at-the-cantor-virtual-global-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Akari Therapeutics to Present at the Cantor Virtual Global Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-541040","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Akari Therapeutics to Present at the Cantor Virtual Global Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-to-present-at-the-cantor-virtual-global-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Akari Therapeutics to Present at the Cantor Virtual Global Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK and LONDON, Sept. 22, 2021 (GLOBE NEWSWIRE) &#8212; Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and\/or leukotriene (LTB4) systems are implicated, today announced that Clive Richardson, Chief Executive Officer, will present at the Cantor Virtual Global Healthcare Conference on Thursday, September 30, 2021 at 1:20 p.m. ET. Investors interested in arranging a virtual meeting with the Company&#8217;s management during the conference should contact the Cantor conference coordinator. A webcast of the Company\u2019s presentation will be available by visiting \u2018Events\u2019 in the Investor Relations section on the Company\u2019s website at www.akaritx.com. A webcast replay will be accessible for 90 days following the event. &hellip; Continue reading &quot;Akari Therapeutics to Present at the Cantor Virtual Global Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-to-present-at-the-cantor-virtual-global-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-22T13:03:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMzMDQxNiM0NDE4MjQ3IzIwMjAyNjM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akari-therapeutics-to-present-at-the-cantor-virtual-global-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akari-therapeutics-to-present-at-the-cantor-virtual-global-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Akari Therapeutics to Present at the Cantor Virtual Global Healthcare Conference\",\"datePublished\":\"2021-09-22T13:03:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akari-therapeutics-to-present-at-the-cantor-virtual-global-healthcare-conference\\\/\"},\"wordCount\":810,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akari-therapeutics-to-present-at-the-cantor-virtual-global-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMzMDQxNiM0NDE4MjQ3IzIwMjAyNjM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akari-therapeutics-to-present-at-the-cantor-virtual-global-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akari-therapeutics-to-present-at-the-cantor-virtual-global-healthcare-conference\\\/\",\"name\":\"Akari Therapeutics to Present at the Cantor Virtual Global Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akari-therapeutics-to-present-at-the-cantor-virtual-global-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akari-therapeutics-to-present-at-the-cantor-virtual-global-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMzMDQxNiM0NDE4MjQ3IzIwMjAyNjM=\",\"datePublished\":\"2021-09-22T13:03:46+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akari-therapeutics-to-present-at-the-cantor-virtual-global-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akari-therapeutics-to-present-at-the-cantor-virtual-global-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akari-therapeutics-to-present-at-the-cantor-virtual-global-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMzMDQxNiM0NDE4MjQ3IzIwMjAyNjM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMzMDQxNiM0NDE4MjQ3IzIwMjAyNjM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akari-therapeutics-to-present-at-the-cantor-virtual-global-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Akari Therapeutics to Present at the Cantor Virtual Global Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Akari Therapeutics to Present at the Cantor Virtual Global Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-to-present-at-the-cantor-virtual-global-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Akari Therapeutics to Present at the Cantor Virtual Global Healthcare Conference - Market Newsdesk","og_description":"NEW YORK and LONDON, Sept. 22, 2021 (GLOBE NEWSWIRE) &#8212; Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and\/or leukotriene (LTB4) systems are implicated, today announced that Clive Richardson, Chief Executive Officer, will present at the Cantor Virtual Global Healthcare Conference on Thursday, September 30, 2021 at 1:20 p.m. ET. Investors interested in arranging a virtual meeting with the Company&#8217;s management during the conference should contact the Cantor conference coordinator. A webcast of the Company\u2019s presentation will be available by visiting \u2018Events\u2019 in the Investor Relations section on the Company\u2019s website at www.akaritx.com. A webcast replay will be accessible for 90 days following the event. &hellip; Continue reading \"Akari Therapeutics to Present at the Cantor Virtual Global Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-to-present-at-the-cantor-virtual-global-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-22T13:03:46+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMzMDQxNiM0NDE4MjQ3IzIwMjAyNjM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-to-present-at-the-cantor-virtual-global-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-to-present-at-the-cantor-virtual-global-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Akari Therapeutics to Present at the Cantor Virtual Global Healthcare Conference","datePublished":"2021-09-22T13:03:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-to-present-at-the-cantor-virtual-global-healthcare-conference\/"},"wordCount":810,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-to-present-at-the-cantor-virtual-global-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMzMDQxNiM0NDE4MjQ3IzIwMjAyNjM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-to-present-at-the-cantor-virtual-global-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-to-present-at-the-cantor-virtual-global-healthcare-conference\/","name":"Akari Therapeutics to Present at the Cantor Virtual Global Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-to-present-at-the-cantor-virtual-global-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-to-present-at-the-cantor-virtual-global-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMzMDQxNiM0NDE4MjQ3IzIwMjAyNjM=","datePublished":"2021-09-22T13:03:46+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-to-present-at-the-cantor-virtual-global-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-to-present-at-the-cantor-virtual-global-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-to-present-at-the-cantor-virtual-global-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMzMDQxNiM0NDE4MjQ3IzIwMjAyNjM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMzMDQxNiM0NDE4MjQ3IzIwMjAyNjM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-to-present-at-the-cantor-virtual-global-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Akari Therapeutics to Present at the Cantor Virtual Global Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/541040","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=541040"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/541040\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=541040"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=541040"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=541040"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}